Advertisement
Canada markets closed

  • S&P/TSX

    22,269.12
    +197.41 (+0.89%)
     

  • S&P 500

    5,277.51
    +42.03 (+0.80%)
     

  • DOW

    38,686.32
    +574.84 (+1.51%)
     

  • CAD/USD

    0.7339
    +0.0028 (+0.38%)
     

  • CRUDE OIL

    77.18
    -0.73 (-0.94%)
     

  • Bitcoin CAD

    92,247.40
    +465.55 (+0.51%)
     

  • CMC Crypto 200

    1,423.32
    -5.24 (-0.37%)
     

  • GOLD FUTURES

    2,347.70
    -18.80 (-0.79%)
     

  • RUSSELL 2000

    2,070.13
    +13.53 (+0.66%)
     

  • 10-Yr Bond

    4.5140
    -0.0400 (-0.88%)
     

  • NASDAQ

    16,735.02
    -2.06 (-0.01%)
     

  • VOLATILITY

    12.92
    -1.55 (-10.71%)
     

  • FTSE

    8,275.38
    +44.33 (+0.54%)
     

  • NIKKEI 225

    38,487.90
    +433.77 (+1.14%)
     

  • CAD/EUR

    0.6762
    +0.0016 (+0.24%)
     

Stocks in play: Microbix Biosystems Inc.

Baystreet.ca

Reports results for its second quarter and first half of fiscal 2024 ended March 31. Q2 revenue was $5,632,901, a 34% increase from Q2 2023 revenues of $4,218,323. Increased sales and higher gross margin dollars led to an operating income and net income of $377,730 versus a Q2 2023 operating income and net income of $31,616. Microbix Biosystems Inc. shares T.MBX are trading up $0.02 at $0.34.

Read: